RxDoctor Payments Data

Brittany Clarke

Family · Milford, OHNPI 1679933238

Payments from drug & device makers

$1,338in general payments, 2019–2025

Across 74 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$166
  • Pfizer$131
  • AstraZeneca$121
  • Johnson & Johnson$114
  • Exact Sciences$106
  • Boehringer Ingelheim$76
  • plus $624 from 24 others

What the payments were for

  • Food & beverage$1,338100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,338 in reported general payments places this provider in the 75th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$23,142
Medicare patients
110
Services billed
348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$60,793
JardianceEmpagliflozin26$40,540
EliquisApixaban28$28,794
LinzessLinaclotide28$25,555
JanuviaSitagliptin Phosphate23$23,483
TrulicityDulaglutide14$19,789
MounjaroTirzepatide13$15,775
Nurtec OdtRimegepant Sulfate13$12,775
Spiriva RespimatTiotropium Bromide15$9,853
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog30$8,783
Advair HfaFluticasone Propion/Salmeterol14$7,905
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,293
SymbicortBudesonide/Formoterol Fumarate23$5,732
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$4,288
Albuterol Sulfate HfaAlbuterol Sulfate145$3,943

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$166$60,79359 claims
Boehringer IngelheimJardiance, Spiriva Respimat$76$50,39341 claims
PfizerEliquis, Nurtec Odt$131$41,56941 claims
Lilly USA, LLCTrulicity, Mounjaro$31$35,56427 claims
AbbVieLinzess$71$25,55528 claims
AstraZenecaBreztri Aerosphere, Symbicort$121$13,02634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,812 family providers in Ohio.

Other family in Milford

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →